In this study, clinical outcomes were evaluated at 5 years post-TIF 2.0. Methods: A total of 63 chronic gastroesophageal reflux disease (GERD) sufferers with troublesome symptoms …

Transoral incisionless fundoplication is a minimally invasive procedure to treat acid reflux, also known as heartburn, and other symptoms associated with chronic gastroesophageal reflux disease (GERD). These symptoms are caused by a malfunctioning valve that allows stomach acid into the esophagus.

2024年2月4日 · Transoral incisionless fundoplication (TIF) is an endoscopic procedure that creates a partial esophagogastric fundoplication for selected nonobese patients with hiatal hernias <2 cm. 8 Accumulated evidence, including sham-controlled and randomized controlled trials comparing PPI and TIF 2.0, show favorable clinical outcomes and low rate of AEs. 10

TIF 2.0 not only creates a larger rotational wrap, but it creates a greater length of valve below the diaphragm. One of the main principles of antireflux surgery is the creation of a valve that is at least 2 to 4 cm, and TIF 2.0 accomplishes this.

The TIF 2.0 procedure with the EsophyX® device uses an incisionless approach to treat the underlying anatomical cause of gastroesophageal reflux disease (GERD) — a chronic condition caused by changes in the gastroesophageal valve (GEV) that allow acid to flow back from the stomach into the esophagus.

Our study shows that TIF using the EsophyX device is safe and effective in reducing atypical GERD symptoms at 6- and 12-month follow-up. It improves patient-centered outcomes and can be a minimally invasive therapeutic option for patients suffering from atypical GERD symptoms on chronic medical therapy.

Transoral incisionless fundoplication (TIF) currently is used to restore the continence of the gastroesophageal junction in selected patients suffering from gastroesophageal reflux disease (GERD), with either a competent gastroesophageal valve or hiatal hernia < 2.5 cm, who refuse or are intolerant or unresponsive to proton pump inhibitor (PPI ...

Results: A total of 85 patients underwent TIF 2.0, and 81 were included in the outcomes analysis. Clinical success was achieved in 94%, GERD Health-Related Quality of Life scores improved …

Secondary end points were symptom improvement, acid exposure time (AET), esophagitis healing, proton pump inhibitor (PPI) use, and satisfaction. Outcomes were assessed at last follow-up within 12 months. Results: A total of 85 patients underwent TIF 2.0, and 81 were included in the outcomes analysis.

2020年9月15日 · Continued evolution of EndoGastric Solutions’ EsophyX technology and concomitant use of TIF 2.0 with hiatal hernia repair brings long-term GERD relief to a broader spectrum of patients